Cargando…
The combination of metabolic syndrome and inflammation increased the risk of colorectal cancer
BACKGROUND: Inflammation and metabolic syndrome (MetS) may act synergistically and possibly accelerate the initiation and progression of colorectal cancer (CRC). We prospectively examined the joint effect of MetS and inflammation on the risk of CRC. METHODS: We studied 92,770 individuals from the Ka...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9307555/ https://www.ncbi.nlm.nih.gov/pubmed/35715516 http://dx.doi.org/10.1007/s00011-022-01597-9 |
_version_ | 1784752789332688896 |
---|---|
author | Liu, Tong Fan, Yali Zhang, Qingsong Wang, Yiming Yao, Nan Song, Mengmeng Zhang, Qi Cao, Liying Song, Chunhua Shi, Hanping |
author_facet | Liu, Tong Fan, Yali Zhang, Qingsong Wang, Yiming Yao, Nan Song, Mengmeng Zhang, Qi Cao, Liying Song, Chunhua Shi, Hanping |
author_sort | Liu, Tong |
collection | PubMed |
description | BACKGROUND: Inflammation and metabolic syndrome (MetS) may act synergistically and possibly accelerate the initiation and progression of colorectal cancer (CRC). We prospectively examined the joint effect of MetS and inflammation on the risk of CRC. METHODS: We studied 92,770 individuals from the Kailuan study. MetS was defined based on the presence of three or more of the following components. (1) high glucose: FPG > 5.6 mmol/L; (2) high blood pressure: SBP ≥ 130 mmHg or DBP ≥ 85 mmHg; (3) high triglycerides: triglycerides > 1.69 mmol/L; (4) low HDL-C: HDL-C < 1.04 mmol/L in men or 1.29 mmol/L in women; and (5) visceral adiposity: waist circumference ≥ 85 cm in men or 80 cm in women. Inflammation was defined as hs-CRP ≥ 3 mg/L. We divided participants into four groups for the primary exposure according to the presence/absence of inflammation and presence/absence of MetS. Cox proportional hazards regression models were used to evaluate the association of MetS and/or inflammation with the risk of CRC. RESULTS: Compared with metabolically healthy noninflammatory individuals, inflammatory participants without MetS and inflammatory participants with MetS were associated with a 1.3-fold and 4.18-fold increased risk of CRC with corresponding HRs (95% CI) of 1.34 (1.09, 1.64) and 4.18 (3.11, 5.62), respectively. The combination of MetS and inflammation was associated with the highest risk of CRC in all subgroups, especially among participants who were female, in younger age, and obese. Sensitivity analyses further validated our primary findings. CONCLUSIONS: We found the combination of MetS and inflammation could significantly increase the risk of CRC. Including CRP in the diagnosis of MetS may help to identify additional high-risk participants who should be targeted for early diagnosis and prevention of CRC. Trial registration Kailuan study, ChiCTR–TNRC–11001489. Registered 24 August, 2011-Retrospectively registered, http:// www.chictr.org.cn/showprojen.aspx?proj=8050 SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00011-022-01597-9. |
format | Online Article Text |
id | pubmed-9307555 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Springer International Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-93075552022-07-24 The combination of metabolic syndrome and inflammation increased the risk of colorectal cancer Liu, Tong Fan, Yali Zhang, Qingsong Wang, Yiming Yao, Nan Song, Mengmeng Zhang, Qi Cao, Liying Song, Chunhua Shi, Hanping Inflamm Res Original Research Article BACKGROUND: Inflammation and metabolic syndrome (MetS) may act synergistically and possibly accelerate the initiation and progression of colorectal cancer (CRC). We prospectively examined the joint effect of MetS and inflammation on the risk of CRC. METHODS: We studied 92,770 individuals from the Kailuan study. MetS was defined based on the presence of three or more of the following components. (1) high glucose: FPG > 5.6 mmol/L; (2) high blood pressure: SBP ≥ 130 mmHg or DBP ≥ 85 mmHg; (3) high triglycerides: triglycerides > 1.69 mmol/L; (4) low HDL-C: HDL-C < 1.04 mmol/L in men or 1.29 mmol/L in women; and (5) visceral adiposity: waist circumference ≥ 85 cm in men or 80 cm in women. Inflammation was defined as hs-CRP ≥ 3 mg/L. We divided participants into four groups for the primary exposure according to the presence/absence of inflammation and presence/absence of MetS. Cox proportional hazards regression models were used to evaluate the association of MetS and/or inflammation with the risk of CRC. RESULTS: Compared with metabolically healthy noninflammatory individuals, inflammatory participants without MetS and inflammatory participants with MetS were associated with a 1.3-fold and 4.18-fold increased risk of CRC with corresponding HRs (95% CI) of 1.34 (1.09, 1.64) and 4.18 (3.11, 5.62), respectively. The combination of MetS and inflammation was associated with the highest risk of CRC in all subgroups, especially among participants who were female, in younger age, and obese. Sensitivity analyses further validated our primary findings. CONCLUSIONS: We found the combination of MetS and inflammation could significantly increase the risk of CRC. Including CRP in the diagnosis of MetS may help to identify additional high-risk participants who should be targeted for early diagnosis and prevention of CRC. Trial registration Kailuan study, ChiCTR–TNRC–11001489. Registered 24 August, 2011-Retrospectively registered, http:// www.chictr.org.cn/showprojen.aspx?proj=8050 SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00011-022-01597-9. Springer International Publishing 2022-06-18 2022 /pmc/articles/PMC9307555/ /pubmed/35715516 http://dx.doi.org/10.1007/s00011-022-01597-9 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Original Research Article Liu, Tong Fan, Yali Zhang, Qingsong Wang, Yiming Yao, Nan Song, Mengmeng Zhang, Qi Cao, Liying Song, Chunhua Shi, Hanping The combination of metabolic syndrome and inflammation increased the risk of colorectal cancer |
title | The combination of metabolic syndrome and inflammation increased the risk of colorectal cancer |
title_full | The combination of metabolic syndrome and inflammation increased the risk of colorectal cancer |
title_fullStr | The combination of metabolic syndrome and inflammation increased the risk of colorectal cancer |
title_full_unstemmed | The combination of metabolic syndrome and inflammation increased the risk of colorectal cancer |
title_short | The combination of metabolic syndrome and inflammation increased the risk of colorectal cancer |
title_sort | combination of metabolic syndrome and inflammation increased the risk of colorectal cancer |
topic | Original Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9307555/ https://www.ncbi.nlm.nih.gov/pubmed/35715516 http://dx.doi.org/10.1007/s00011-022-01597-9 |
work_keys_str_mv | AT liutong thecombinationofmetabolicsyndromeandinflammationincreasedtheriskofcolorectalcancer AT fanyali thecombinationofmetabolicsyndromeandinflammationincreasedtheriskofcolorectalcancer AT zhangqingsong thecombinationofmetabolicsyndromeandinflammationincreasedtheriskofcolorectalcancer AT wangyiming thecombinationofmetabolicsyndromeandinflammationincreasedtheriskofcolorectalcancer AT yaonan thecombinationofmetabolicsyndromeandinflammationincreasedtheriskofcolorectalcancer AT songmengmeng thecombinationofmetabolicsyndromeandinflammationincreasedtheriskofcolorectalcancer AT zhangqi thecombinationofmetabolicsyndromeandinflammationincreasedtheriskofcolorectalcancer AT caoliying thecombinationofmetabolicsyndromeandinflammationincreasedtheriskofcolorectalcancer AT songchunhua thecombinationofmetabolicsyndromeandinflammationincreasedtheriskofcolorectalcancer AT shihanping thecombinationofmetabolicsyndromeandinflammationincreasedtheriskofcolorectalcancer AT liutong combinationofmetabolicsyndromeandinflammationincreasedtheriskofcolorectalcancer AT fanyali combinationofmetabolicsyndromeandinflammationincreasedtheriskofcolorectalcancer AT zhangqingsong combinationofmetabolicsyndromeandinflammationincreasedtheriskofcolorectalcancer AT wangyiming combinationofmetabolicsyndromeandinflammationincreasedtheriskofcolorectalcancer AT yaonan combinationofmetabolicsyndromeandinflammationincreasedtheriskofcolorectalcancer AT songmengmeng combinationofmetabolicsyndromeandinflammationincreasedtheriskofcolorectalcancer AT zhangqi combinationofmetabolicsyndromeandinflammationincreasedtheriskofcolorectalcancer AT caoliying combinationofmetabolicsyndromeandinflammationincreasedtheriskofcolorectalcancer AT songchunhua combinationofmetabolicsyndromeandinflammationincreasedtheriskofcolorectalcancer AT shihanping combinationofmetabolicsyndromeandinflammationincreasedtheriskofcolorectalcancer |